Enhanced surveillance of notifications of hepatitis C to Queensland Health up to 19 years previously
DOI:
https://doi.org/10.33321/cdi.2023.47.63Keywords:
hepatitis C, notifiable diseases, follow-up, testing, treatment, enhanced surveillanceAbstract
In this study we aimed to assess the utility of following up historical hepatitis C notifications for enhanced surveillance and linking cases to further testing and treatment. Queensland hepatitis C notifications from June 2018, 2013, 2008 and 2003 who were not incarcerated at the time of testing were followed up. The most recent identified clinicians for cases were contacted by telephone. When no information about a current clinician was available, the case was contacted via a letter or text message. Clinicians and cases were encouraged to pursue further testing and treatment and provide information about management. Following notification but prior to this study’s follow-up, a majority of cases (309/532; 58%) had a negative polymerase chain reaction (PCR) test or underwent treatment.Clinician follow-up was successful in 21% of eligible cases, with the proportion decreasing with increasing time since notification. In conclusion, contacting clinicians to link notified cases to further testing and treatment may increase testing and treatment in a small proportion of cases notified up to nine years post-notification. From our experience, the follow-up of notifications before this time is unlikely to result in improved outcomes.
Downloads
References
Australian Government Department of Health and Aged Care. Fourth National Hepatitis C Strategy 2014–2017. Canberra: Australian Government Department of Health and Aged Care; 2014. Available from: https://healthinfonet.ecu.edu.au/learn/health-topics/infectious-conditions/policies-and-strategies/31148/.
World Health Organization (WHO). Global health sector strategy on viral hepatitis 2016–2021. Towards ending viral hepatitis. Geneva: WHO; June 2016. [Accessed on 5 August 2017.] Available from: https://apps.who.int/iris/handle/10665/246177.
Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65(4):727–33. doi: https://doi.org/10.1016/j.jhep.2016.06.015.
Scott N, Iser DM, Thompson AJ, Doyle JS, Hellard ME. Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia. J Gastroenterol Hepatol. 2016;31(4):872–82. doi: https://doi.org/10.1111/jgh.13223.
Dore GJ, Hajarizadeh B. Elimination of hepatitis C virus in Australia: laying the foundation. Infect Dis Clin North Am. 2018;32(2):269–79. doi: https://doi.org/10.1016/j.idc.2018.02.006.
Burnet Institute, Kirby Institute. Australia’s progress towards hepatitis C elimination Annual Report 2022. Melbourne: Burnet Institute; 2022. Available from: https://www.burnet.edu.au/knowledge-and-media/research-reports-plus-policy-briefs/australia-s-progress-towards-hepatitis-c-elimination-annual-report-2022/.
Hepatitis C Virus Infection Consensus Statement Working Group. Australian recommendations for the management of hepatitis C virus infection: a consensus statement (June 2020). Melbourne: Gastroenterological Society of Australia; 2020. Available from: https://ashm.blob.core.windows.net/ashmpublic/hepatitis-C-virus-infection-a-consensus-statement-Jun-2020.pdf.
Lafferty L, Treloar C, Guthrie J, Chambers GM, Butler T. Social capital strategies to enhance hepatitis C treatment awareness and uptake among men in prison. J Viral Hepat. 2017;24(2):111–6. doi: https://doi.org/10.1111/jvh.12627.
Mina MM, Herawati L, Butler T, Lloyd A. Hepatitis C in Australian prisons: a national needs assessment. Int J Prison Health. 2016;12(1):3–16. doi: https://doi.org/10.1108/IJPH-08-2015-0025.
Iversen J, Dore GJ, Catlett B, Cunningham P, Grebely J, Maher L. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia. J Hepatol. 2019;70(1):33–9. doi: https://doi.org/10.1016/j.jhep.2018.09.030.
Graham S, Harrod ME, Iversen J, Hocking JS. Prevalence of hepatitis C among Australian Aboriginal and Torres Strait Islander people: a systematic review and meta-analysis. Hepat Mon. 2016;16(7):e38640. doi: https://doi.org/10.5812/hepatmon.38640.
Heard E, Massi L, Smirnov A, Selvey L. Prescribing direct‐acting antivirals to treat hepatitis C virus in a general practice setting in Australia: “So why not do it”? Intern Med J. 2020;50(9):1053–8. doi: https://doi.org/10.1111/imj.14648.
Beiser M, Leon C, Gaeta JM. Needs assessment of HCV-infected individuals experiencing homelessness and implications. J Health Care Poor Underserved. 2017;28(1):596–606. doi: https://doi.org/10.1353/hpu.2017.0042.
Brener L, Wilson H, Jackson LC, Johnson P, Saunders V, Treloar C. Experiences of diagnosis, care and treatment among Aboriginal people living with hepatitis C. Aust N Z J Public Health. 2016;40(Suppl 1):S59–64. doi: https://doi.org/10.1111/1753-6405.12402.
Day E, Hellard M, Treloar C, Bruneau J, Martin NK, Øvrehus A et al. Hepatitis C elimination among people who inject drugs: challenges and recommendations for action within a health systems framework. Liver Int. 2019;39(1):20–30. doi: https://doi.org/10.1111/liv.13949.
Morales-Arraez D, Alonso-Larruga A, Diaz-Flores F, Garcia Dopico JA, de Vera A, Quintero E et al. Predictive factors for not undergoing RNA testing in patients found to have hepatitis C serology and impact of an automatic alert. J Viral Hepat. 2019;26(9):1117–23. doi: https://doi.org/10.1111/jvh.13122.
Kracht PAM, Arends JE, van Erpecum KJ, Thijsen SFT, Vlaminckx BJM, Weersink AJL et al. REtrieval And cure of Chronic Hepatitis C (REACH): results of micro-elimination in the Utrecht province. Liver Int. 2019;39(3):455–62. doi: https://doi.org/10.1111/liv.13959.
Queensland State Government. Public Health Act 2005: Public Health Regulation 2018. [Legislation.] Brisbane: Queensland State Government; 2 December 2022. Available from: https://www.legislation.qld.gov.au/view/pdf/inforce/current/sl-2018-0117.
Steininger L, Chromy D, Bauer D, Simbrunner B, Binter T, Schwabl P et al. Direct patient-physician communication via a hepatitis C hotline facilitates treatment initiation in patients with poor adherence. Wien Klin Wochenschr. 2021;133(9–10):452–60. doi: https://doi.org/10.1007/s00508-020-01790-y.
Walker S, Wallace J, Latham N, Saich F, Pedrana A, Hellard M et al. “It’s time!”: a qualitative exploration of the acceptability of hepatitis C notification systems to help eliminate hepatitis C. Int J Drug Policy. 2021;97:103280. doi: https://doi.org/10.1016/j.drugpo.2021.103280.
Webster R, Moore MS, Bocour A, Johnson N, Winters A. Health department efforts to increase hepatitis C RNA testing among people appearing out of care: comparison of outreach approaches, New York City, 2017. Public Health Rep. 2020;135(6):823–30. doi: https://doi.org/10.1177/0033354920952068.
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
